Do not use unless the solution is clear and the seal is
Administration of zinc in the absence of copper may cause
a decrease in serum copper levels.
Copper 0.4 mg/mL (Cupric Chloride Injection, USP) should
only be used in conjunction with a pharmacy directed admixture program using
aseptic technique in a laminar flow environment; it should be used promptly and
in a single operation without any repeated penetrations. Solution contains no preservatives;
discard unused portion immediately after admixture procedure is completed.
It is not recommended to administer copper to a patient
with Wilson's Disease, a genetic disease of copper metabolism.
Carcinogenesis, Mutagenesis, And Impairment Of Fertility
Long-term animal studies to evaluate the carcinogenic
potential of Copper 0.4 mg/mL (Cupric Chloride Injection, USP) have not been
performed, nor have studies been done to assess mutagenesis or impairment of
It is not known whether this drug is excreted in human
milk. Because many drugs are excreted in human milk, caution should be
exercised when Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is administered
to a nursing woman.
(See DOSAGE AND ADMINISTRATION section.) There are
limited data in infants weighing less than 1500 grams.
Pregnancy Category C
Animal reproduction studies have not been conducted with
cupric chloride. It is also not known whether cupric chloride can cause fetal
harm when administered to a pregnant woman or can affect reproductive capacity.
Cupric chloride should be given to a pregnant woman only if clearly indicated.
An evaluation of current literature revealed no clinical
experience identifying differences in response between elderly and younger
patients. In general, dose selection for an elderly patient should be cautious,
usually starting at the low end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal, or cardiac function, and of concomitant
disease or other drug therapy.